Cafestol is a coffee-specific diterpene alcohol found in the lipid fraction of coffee beans and in coffee oils, including the coffee bean oil record already present in the AromaForge archive. Public evidence supports cafestol much more strongly as a dietary coffee constituent than as a fragrance constituent: chemistry identity is clear, coffee-oil occurrence is documented, and both mechanistic and human literature repeatedly connect cafestol-rich unfiltered coffee with increases in serum cholesterol markers. Archive-safe positioning is that cafestol is a well-defined coffee diterpene with meaningful research relevance and a notable oral-exposure safety context, not a constituent that should be marketed with broad wellness claims.
Chemical identity and composition
PubChem lists cafestol as C20H28O3 with a diterpene alcohol structure. It is routinely described in coffee chemistry literature as a coffee-specific diterpene concentrated in the lipid fraction of beans and retained more strongly in unfiltered coffee preparations than in paper-filtered coffee. In the archive's coffee bean oil record, cafestol is included as a minor quantified marker from a recent review source.
Aroma and practical use
- Use the recorded coffee-like, oily, faintly resinous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
cholesterol homeostasis mechanism
A mechanistic study concluded that cafestol acts as an agonist ligand for both FXR and PXR, with downstream effects on CYP7A1 and related bile-acid homeostasis genes that may contribute to cholesterol changes.
Measured: FXR/PXR activation and bile-acid homeostasis gene expression
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
human lipid changes
PubMed-indexed human research reports that coffee diterpenes including cafestol strongly raise VLDL and LDL cholesterol and can slightly reduce HDL cholesterol in humans when present in unfiltered coffee.
Measured: serum VLDL, LDL, HDL, triglycerides
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
nrf2 detox response
In preclinical models, coffee and the diterpene pair cafestol plus kahweol increased detoxification-enzyme expression in a largely Nrf2-dependent manner and increased resistance to acrolein injury in wild-type fibroblasts.
Measured: NQO1, GSTA1, UGT1A6, GCLC expression and acrolein resistance
This experimental finding does not establish benefit, dose or safety in people using this blend.
coffee oil occurrence
A 2024 coffee-oil review summarized roasted coffee oil composition data and reported cafestol around 1.74% in one cited profile, supporting its inclusion as a minor constituent of coffee bean oil in the archive.
Measured: reported roasted coffee oil composition
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The main public safety signal for cafestol concerns oral intake from unfiltered coffee, where repeated exposure is associated with cholesterol-raising effects.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
A 2024 open-access review discussing cafestol roasting derivatives states that a daily intake of 10 mg cafestol over four weeks increases serum cholesterol by about 5 mg/dL, reflecting the best-known adverse context in humans.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No constituent-specific dermal limit, sensitization threshold, or phototoxicity study for isolated cafestol was located in the reviewed public sources for this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
fxr and pxr agonism
Cafestol has been shown in mechanistic work to act as an agonist ligand for FXR and PXR, helping explain its effects on bile-acid and cholesterol homeostasis.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
nrf2 linked detox enzyme induction
Cell and animal work suggests cafestol can contribute to induction of NQO1 and related detoxification enzymes through Nrf2-linked signaling, usually studied together with kahweol.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Much of the positive-language cafestol literature is preclinical and often studies cafestol together with kahweol, so constituent-only benefit framing would overstate the evidence.
- No human fragrance-use, inhalation-use, or dermal-use outcomes specific to isolated cafestol were located in the reviewed public sources.
- A c6 verification search (2026-07-13) found no RIFM/IFRA assessment or dermal-limit citation for cafestol; the prior 0.1% dermal_limit_pct had no supporting source and was corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.